BACKGROUND: Among older persons, we previously endorsed a two-step spirometric definition of chronic obstructive pulmonary disease (COPD) that requires a ratio of forced expiratory volume in 1sec to forced vital capacity (FEV(1)/FVC) below .70, and an FEV(1) below the 5th or 10th standardized residual percentile ("SR-tile strategy"). OBJECTIVE: To evaluate the clinical validity of an SR-tile strategy, compared to a current definition of COPD, as published by the Global Initiative for Obstructive Lung Disease (GOLD-COPD), in older persons. METHODS: We assessed national data from 2480 persons aged 65-80 years. In separate analyses, we evaluated the association of an SR-tile strategy with mortality and respiratory symptoms, relative to GOLD-COPD. As per convention, GOLD-COPD was defined solely by an FEV(1)/FVC<.70, with severity staged according to FEV(1) cut-points at 80 and 50 percent predicted (%Pred). RESULTS: Among 831 participants with GOLD-COPD, the risk of death was elevated only in 179 (21.5%) of those who also had an FEV(1)<5th SR-tile; and the odds of having respiratory symptoms were elevated only in 310 (37.4%) of those who also had an FEV(1)<10th SR-tile. In contrast, GOLD-COPD staged at an FEV(1) 50-79%Pred led to misclassification (overestimation) in terms of 209 (66.4%) and 77 (24.6%) participants, respectively, not having an increased risk of death or likelihood of respiratory symptoms. CONCLUSION: Relative to an SR-tile strategy, the majority of older persons with GOLD-COPD had neither an increased risk of death nor an increased likelihood of respiratory symptoms. These results raise concerns about the clinical validity of GOLD guidelines in older persons. Published by Elsevier Ltd.
BACKGROUND: Among older persons, we previously endorsed a two-step spirometric definition of chronic obstructive pulmonary disease (COPD) that requires a ratio of forced expiratory volume in 1sec to forced vital capacity (FEV(1)/FVC) below .70, and an FEV(1) below the 5th or 10th standardized residual percentile ("SR-tile strategy"). OBJECTIVE: To evaluate the clinical validity of an SR-tile strategy, compared to a current definition of COPD, as published by the Global Initiative for Obstructive Lung Disease (GOLD-COPD), in older persons. METHODS: We assessed national data from 2480 persons aged 65-80 years. In separate analyses, we evaluated the association of an SR-tile strategy with mortality and respiratory symptoms, relative to GOLD-COPD. As per convention, GOLD-COPD was defined solely by an FEV(1)/FVC<.70, with severity staged according to FEV(1) cut-points at 80 and 50 percent predicted (%Pred). RESULTS: Among 831 participants with GOLD-COPD, the risk of death was elevated only in 179 (21.5%) of those who also had an FEV(1)<5th SR-tile; and the odds of having respiratory symptoms were elevated only in 310 (37.4%) of those who also had an FEV(1)<10th SR-tile. In contrast, GOLD-COPD staged at an FEV(1) 50-79%Pred led to misclassification (overestimation) in terms of 209 (66.4%) and 77 (24.6%) participants, respectively, not having an increased risk of death or likelihood of respiratory symptoms. CONCLUSION: Relative to an SR-tile strategy, the majority of older persons with GOLD-COPD had neither an increased risk of death nor an increased likelihood of respiratory symptoms. These results raise concerns about the clinical validity of GOLD guidelines in older persons. Published by Elsevier Ltd.
Authors: Dhanunjaya R Lakkireddy; Manohar S Gowda; Caroline W Murray; Krishnamohan R Basarakodu; James L Vacek Journal: Am J Med Date: 2004-10-01 Impact factor: 4.965
Authors: Bartolome R Celli; Claudia G Cote; Jose M Marin; Ciro Casanova; Maria Montes de Oca; Reina A Mendez; Victor Pinto Plata; Howard J Cabral Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Carolyn L Rochester; H Klar Yaggi; Thomas M Gill Journal: Respir Med Date: 2009-05-21 Impact factor: 3.415
Authors: Carlos A Vaz Fragoso; Thomas M Gill; Gail McAvay; Henry Klar Yaggi; Peter H Van Ness; John Concato Journal: J Investig Med Date: 2011-10 Impact factor: 2.895
Authors: Amit D Parulekar; Carlos Martinez; Chu-Lin Tsai; Nicholas Locantore; Mustafa Atik; Abebaw M Yohannes; Christina C Kao; Hassan Al-Azzawi; Ali Mohsin; Robert A Wise; Marilyn G Foreman; Dawn L Demeo; Elizabeth A Regan; Barry J Make; Aladin M Boriek; Laura E Wiener; Nicola A Hanania Journal: J Am Med Dir Assoc Date: 2017-12-01 Impact factor: 4.669
Authors: Carlos A Vaz Fragoso; Thomas M Gill; Gail McAvay; Peter H Van Ness; H Klar Yaggi; John Concato Journal: Respir Care Date: 2011-05-20 Impact factor: 2.258
Authors: Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera Journal: Lung India Date: 2013-07
Authors: Surya P Bhatt; Jessica C Sieren; Mark T Dransfield; George R Washko; John D Newell; Douglas S Stinson; Gideon K D Zamba; Eric A Hoffman Journal: Thorax Date: 2013-03-23 Impact factor: 9.139